- Home
- ALZN vs NRSN Comparison
ALZN vs NRSN Comparison
Compare ALZN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALZN | NRSN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALZN | NRSN |
|---|---|---|
| Price | $1.28 | $3.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $78.50 |
| AVG Volume (30 Days) | ★ 62.3K | 15.7K |
| Earning Date | 09-10-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $0.25 |
| 52 Week High | $2.68 | $7.50 |
Technical Indicators
Market Signals| Indicator | ALZN | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 41.70 |
| Support Level | $1.20 | $0.63 |
| Resistance Level | $2.20 | $7.50 |
| Average True Range (ATR) | 0.14 | 0.46 |
| MACD | -0.03 | -0.33 |
| Stochastic Oscillator | 18.46 | 7.49 |
Price Performance
Historical ComparisonAbout ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.